Plus Therapeutics Presents Analysis Showing CNSide May Reduce Leptomeningeal Metastases Costs by 40%

Health economics data highlights potential value of earlier diagnosis using CNSide diagnostic as it enters U.S. commercialization

Mar. 19, 2026 at 12:19pm

Got story updates? Submit your updates here. ›

Plus Therapeutics, a healthcare company developing precision diagnostics and radiopharmaceuticals for central nervous system cancers, announced the presentation of a new health economics study evaluating the economic impact of earlier detection and therapeutic management of leptomeningeal metastases (LM) using the CNSide cerebrospinal fluid (CSF) assay. The analysis suggests that earlier LM diagnosis and treatment enabled by CNSide may reduce overall LM-related healthcare costs by approximately 40%, primarily through earlier therapeutic intervention, improved treatment precision, and reduced hospitalizations.

Why it matters

Leptomeningeal metastases is a rare but severe complication of advanced cancer, with a median survival of just 2-6 months and limited effective treatment options. The health economics data demonstrating the potential cost savings and improved outcomes from earlier LM detection using CNSide is important for payers and health systems evaluating adoption of this advanced diagnostic.

The details

The cost-of-care analysis utilized published literature, real-world data, and healthcare claims databases to estimate the substantial direct and indirect costs associated with late-stage LM diagnosis, which can exceed $100,000 per month due to repeated imaging, LM-directed therapies, and palliative care. The analysis found that earlier detection and treatment optimization enabled by CNSide may reduce overall LM-related healthcare costs by around 40%, driven by factors like earlier therapeutic intervention, improved treatment precision, reduced adverse events and hospitalizations, and gains in quality-adjusted life years.

  • The data will be presented at the ISPOR 2026 Annual Meeting in Philadelphia, PA on May 17-20, 2026.

The players

Plus Therapeutics, Inc.

A clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system.

CNSide Diagnostics, LLC

A wholly owned subsidiary of Plus Therapeutics that develops and commercializes proprietary laboratory-developed tests like the CNSide CSF Assay Platform to identify tumor cells that have metastasized to the central nervous system.

Russ Havranek

Executive Vice President, Commercial and Corporate Strategy of Plus Therapeutics.

Harvard T.H. Chan School of Public Health

Co-author of the health economics analysis on the economic impact of earlier detection and therapeutic management of leptomeningeal metastases using CNSide.

Got photos? Submit your photos here. ›

What they’re saying

“CNSide's ability to detect and monitor tumor cells in cerebrospinal fluid provides clinicians with actionable information earlier in the disease course.”

— Russ Havranek, EVP, Commercial and Corporate Strategy

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This health economics analysis highlights the substantial healthcare costs associated with late-stage leptomeningeal metastases and the potential value of earlier diagnosis and treatment optimization using the CNSide diagnostic tool as it enters U.S. commercialization. The data supports the clinical and economic benefits of this advanced diagnostic for payers and health systems evaluating its adoption.